[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-368701-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-368701-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","low-levels-of-tumor-suppressor-mir-3619-in-plasma-contribute-to-malignant-outcomes-and-a-target-for-nucleic-acid-therapy-in-esophageal-cancer","Low levels of tumor suppressor miR-3619 in plasma contribute to malignant outcomes and a target for nucleic acid therapy in esophageal cancer","","Reduced circulating tumor-suppressing microRNAs (miRNAs) are linked to cancer progression and poor prognosis. This study tested tumor suppressor miR-3619-5p in esophageal squamous cell carcinoma (ESCC) using analyses derived from NCBI and miRNA databases, including both test-scale and large-scale cohorts. Plasma miR-3619-5p was markedly lower in ESCC patients, associated with advanced pathological stage, and recognized as an independent prognostic marker. Overexpression inhibited ESCC proliferation, migration, and invasion via direct suppression of PIM1, and increasing circulating miR-3619-5p in vivo suppressed tumor growth, supporting nucleic acid therapy targeting PIM1.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/low-levels-of-tumor-suppressor-mir-3619-in-plasma-contribute-to-malignant-outcomes-and-a-target-for-nucleic-acid-therapy-in-esophageal-cancer/368701/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/low-levels-of-tumor-suppressor-mir-3619-in-plasma-contribute-to-malignant-outcomes-and-a-target-for-nucleic-acid-therapy-in-esophageal-cancer/368701.png","ImageObject",300,407,{"name":42,"@type":43},"Pentious","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does the study connect plasma miR-3619-5p to ESCC outcomes?","Question",{"text":63,"@type":64},"Plasma miR-3619-5p levels were markedly lower in ESCC patients than in healthy volunteers. Lower levels correlated with advanced pathological stages and acted as an independent prognostic marker.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What mechanism did the study propose for miR-3619-5p’s effects in ESCC?",{"text":68,"@type":64},"Overexpression of miR-3619-5p inhibited ESCC proliferation, migration, and invasion by directly suppressing PIM1.",{"name":70,"@type":61,"acceptedAnswer":71},"What evidence supports nucleic-acid therapy targeting PIM1?",{"text":72,"@type":64},"In vivo, increased plasma levels of miR-3619-5p after subcutaneous injection in mice bearing ESCC tumors significantly inhibited tumor growth, with low PIM1 expression in tumors.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},368701,1790200722,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nLow levels of tumor suppressor miR-3619 in plasma contribute to malignant outcomes and a target for nucleic acid therapy in esophageal cancer  \nHiroshi Arakawa1,2, Shuhei Komatsu1,2􀀍, Takuma Kishimoto1,2, Hajime Kamiya1, Ryo Ishida1, Yusuke Takashima1, Keiji Nishibeppu1, Jun Kiuchi1, Taisuke Imamura1, Takuma Ohashi1, Hiroki Shimizu1, Tomohiro Arita1, Hirotaka Konishi1, Atsushi Shiozaki1, Takeshi Kubota1, Hitoshi Fujiwara1 & Eigo Otsuji1  \nRecent studies indicate that reduced levels of certain tumor-suppressing microRNAs (miRNAs) circulating in the blood are linked to tumor progression and poor prognosis across various types of malignancies. Identified from a comprehensive analysis of the NCBI and miRNA databases, we tested tumor suppressor miR-3619-5p in esophageal squamous cell carcinoma (ESCC) . Both test-scale and large-scale analyses demonstrated that plasma levels of miR-3619-5p were markedly lower in ESCC patients than in healthy volunteers. Lower plasma levels of miR-3619-5p showed a strong association with advanced pathological stages and were recognized as an independent prognostic marker. Overexpression of miR-3619-5p in ESCC cells inhibited cell proliferation, migration and invasion through the direct suppression of novel target protein, proviral insertion site in Moloney murine leukemia virus 1 (PIM1). PIM1 is overexpressed in various solid and hematological cancers including ESCC, and has proven to be a promising target of inhibitors in recent clinical trials. In vivo, increased plasma 3619-5p levels following subcutaneous injection in mice bearing ESCC tumors significantly inhibited tumor growth, with low expression of PIM1 in tumor. Until now, no study has demonstrated that the secretory-type miRNA such as miR-3619-5p could contribute to nucleic acid therapy to PIM1 . Reduced blood levels of miR-3619-5p are linked to ESCC progression and poor prognosis, suggesting that miR-3619-5p could act as a novel therapeutic focus for nucleic acid-based treatment targeting PIM1 in ESCC patients.  \nKeywords Biomarker, Nucleic acid therapy, Esophageal cancer, Plasma MicroRNA, In vivo model of nucleic acid therapy  \nGlobally, esophageal cancer ranks sixth in mortality rates, contributing significantly to cancer death statistics1. Esophageal cancer is typically classified into two histological types: adenocarcinoma and squamous cell carcinoma2. In Western countries, adenocarcinoma is the predominant form of esophageal cancer. In contrast, within the “esophageal cancer belt,” a region spanning from northern Iran through Central Asia to north-central China, esophageal squamous cell carcinoma (ESCC) accounts for roughly 90% of all cases1. In recent years, remarkable advancements have been seen in chemotherapy, radiotherapy, surgical procedures, and perioperative management for ESCC. Despite advancements in treatment, the 5-year survival rate for individuals with ESCC continues to hover around 20%3. To enhance patient outcomes, many studies have focused on elucidating the molecular mechanisms of tumorigenesis in ESCC, as well as identifying potential clinical biomarkers and therapeutic molecular targets. However, for ESCC there are still only a few early diagnostic biomarkers and therapeutic targets4,5.  \n1Division of Digestive Surgery, Department of Surgery, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachihirokoji, Kamigyo-ku, Kyoto 602-8566, Japan. 2Hirosh Arakawa, Shuhei Komatsu and Takuma Kishimoto equally contributed to this work. 􀀍 email: [skomatsu@koto.kpu-m.ac.jp](skomatsu@koto.kpu-m.ac.jp)  \n[www. nature.com/scientificreports/](www. nature.com/scientificreports/)  \nDiscovered in 1993, microRNAs (miRNAs) are small, non-coding RNA molecules that regulate gene expression by destabilizing mRNA and inhibiting its translation. Numerous studies have revealed altered miRNA expression associated with the onset and development of dive","cbCaieC6R5j0oSk6","https://ap.wps.com/l/cbCaieC6R5j0oSk6","pdf",4235059,13,"English","# Background\n## Circulating microRNAs as biomarkers\n## ESCC burden and unmet needs\n\n# Study focus and approach\n## Identification of miR-3619-5p\n## Patient-level plasma analyses\n\n# Mechanistic findings\n## Association with stage and prognosis\n## PIM1 as a direct target\n## Cellular effects in ESCC\n\n# In vivo therapeutic implications\n## Nucleic-acid-based modulation of miR-3619-5p\n## Tumor growth inhibition in an animal model","[{\"question\":\"How does the study connect plasma miR-3619-5p to ESCC outcomes?\",\"answer\":\"Plasma miR-3619-5p levels were markedly lower in ESCC patients than in healthy volunteers. Lower levels correlated with advanced pathological stages and acted as an independent prognostic marker.\"},{\"question\":\"What mechanism did the study propose for miR-3619-5p’s effects in ESCC?\",\"answer\":\"Overexpression of miR-3619-5p inhibited ESCC proliferation, migration, and invasion by directly suppressing PIM1.\"},{\"question\":\"What evidence supports nucleic-acid therapy targeting PIM1?\",\"answer\":\"In vivo, increased plasma levels of miR-3619-5p after subcutaneous injection in mice bearing ESCC tumors significantly inhibited tumor growth, with low PIM1 expression in tumors.\"}]","Low levels of tumor suppressor miR-3619 in plasma contribute to malignant outcomes and a target for nucleic acid therapy in esophageal cancer | PDF",1790178121,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/90c819f71e815fa592f13972698dab65.webp",983,1291,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0cc7cef5388f0e38563a21ffee2e3af9.webp",982,1290,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8fb0a5c1226fd4ab71cb29377a4ba6f2.webp",981,1289,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/261dd483a34a7887980c1393535faefd.webp",980,1287]